Vitamin d boosts chemo response in colorectal cancer patients?
NCT ID NCT07241247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether taking vitamin D supplements can help people with stage II or III colorectal cancer who are receiving chemotherapy. The researchers measured markers of cell death and inflammation in 44 patients before and after 6 months of vitamin D. The goal was to see if vitamin D could improve tumor response and reduce inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
44 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with histologically and radiologically confirmed diagnosis of stage II or III colorectal cancer. * Performance status 0-1 according to the Eastern Cooperative Oncology Group (ECOG). * Patients who received FOLFOX or XELOX as first line chemotherapy. * Both genders. * Age ≥18. * Patients with adequate hematologic parameters (white blood cell count ≥3000/mm3, granulocytes ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥ 8 gm/l). * Patients with normal renal functions. * Patients with normal hepatic functions. * Patients with sufficient 25(OH) Vitamin D level (30-100 ng/mL). Exclusion Criteria: * Patients with metastatic colorectal cancer (CRC). * Patients with parathyroid disorders. * Patients who are taking vitamin D-containing supplements (\>800 IU/day) unless they discontinued vitamin D supplementation at least 2 months prior to enrollment. * Patients had a history of hypercalcemia.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colo-rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Menofia university
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a platform trial match the right drug combo to each tumor?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a registry make endoscopic procedures safer and more effective?
- Can extra weight complicate colorectal surgery? a new study investigates
- A new clue in the fight against colorectal cancer recurrence?